HOLX

HOLX

USD

Hologic Inc. Common Stock

$64.845+0.365 (0.566%)

Reaalajas hind

Healthcare
Medical Instruments & Supplies
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$64.480

Kõrge

$64.990

Madal

$64.190

Maht

2.63M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

14.5B

Tööstusharu

Medical Instruments & Supplies

Riik

United States

Kauplemisstatistika

Keskmine maht

3.66M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $51.9Praegune $64.845Kõrge $84.67

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 11. juuni 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

HOLX: Hologic Inc. Common Stock – Unpacking Recent Trends and Future Signals

Stock Symbol: HOLX Generate Date: 2025-06-11 07:39:29

Let's break down what's been happening with Hologic and what the data might be telling us. This company, Hologic, operates in the healthcare sector, specifically focusing on medical instruments and supplies for women's health. They're involved in everything from diagnostics to surgical products.

The Latest Buzz: News Sentiment

Recent news for Hologic paints a pretty interesting picture.

First, we saw Needham, an analyst firm, simply reiterate their "Hold" rating on Hologic. This isn't an upgrade or a downgrade; it just means they're sticking with their previous view. It's a neutral signal, suggesting they don't see a strong reason to either buy or sell aggressively right now. It's like saying, "Keep an eye on it, but no big moves needed."

Then, there's more positive news about Hologic presenting new data at ASCO 2025. This data highlights the significant impact of their Breast Cancer Index® Test. This test helps doctors figure out if patients with a certain type of breast cancer (HR+) will benefit from extended hormone therapy. This kind of news is generally good for a medical device company. It shows innovation, potential for better patient outcomes, and could lead to wider adoption of their products. So, while one piece of news was neutral, the other points to positive developments on the product front.

Overall, the news sentiment leans slightly positive, driven by the promising clinical data, even with the analyst firm holding steady.

Price Check: What the Stock Has Been Doing

Looking at the past 30 days, Hologic's stock has seen some notable shifts. Back in early May, the price dipped quite a bit, even hitting a 52-week low of $51.90 on May 2nd. But then, something changed. Around May 7th, we saw a massive jump in volume and price, with the stock moving from the low $50s up into the mid-$50s.

More recently, specifically around May 27th, the stock experienced a significant surge. It jumped from the mid-$50s to over $62, and then continued climbing. The volume during this period was exceptionally high, indicating a lot of buying interest. This kind of sharp upward movement, especially with heavy trading, often signals strong conviction from buyers.

As of the last recorded close, the stock was at $65.14. This is a solid recovery from its earlier lows and shows a clear upward trend in the very short term. The average daily volume for Hologic is typically around 3.6 million shares, but on May 27th, it shot up to over 19 million, and on May 28th, it was still very high at 8.7 million. This tells us there was a lot of action and interest during that price jump.

Putting It All Together: Outlook & Strategy Ideas

Considering the recent news, the strong price surge, and what the AI model is predicting, Hologic seems to be in a bullish phase right now.

The positive news about the Breast Cancer Index® Test likely contributed to the recent price jump, as it highlights the company's value in a critical medical area. The AI model from AIPredictStock.com is also quite optimistic, forecasting a 0.29% increase today, a 1.44% rise tomorrow, and a 2.26% jump the day after. These are decent short-term gains if they materialize.

So, what does this suggest? The current situation appears to favor potential buyers, indicating a possible 'buy' or 'accumulate' window, especially for those looking at short-term trading.

  • Potential Entry Consideration: Given the current price of $65.14 and the AI's upward predictions, an entry around the current price or on any slight dip towards the $64.94 support level (as highlighted by technical indicators) could be considered. The strong buying pressure and bullish technical signals (like the MACD golden cross and high OBV) support this idea.
  • Potential Exit/Stop-Loss Consideration: For managing risk, a stop-loss could be placed below a recent support level, perhaps around $58.63. This level is identified as a stop-loss point in the recommendation data and is well below the recent surge, offering a buffer. For taking profits, the AI projects an upward trend, and the analyst average price target is $67.27. A more aggressive take-profit target could be around $69.19, as suggested by the recommendation data.

Company Context

It's worth remembering that Hologic is a significant player in the Medical Instruments & Supplies industry within the Healthcare sector. Their focus on women's health means that advancements in areas like breast cancer diagnostics, as seen in the recent news, are directly tied to their core business and future growth. While their P/E ratio is neutral and revenue growth has been negative, the strong positive sentiment from recent news and analyst upgrades, combined with the technical breakout, are currently driving the stock's momentum. The company's large market cap ($14.5 billion) also suggests a well-established presence.


Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Investing in stocks involves risks, and past performance is not indicative of future results. Always conduct your own thorough research or consult with a qualified financial professional before making any investment decisions.

Seotud uudised

Analyst Upgrades

Needham Reiterates Hold on Hologicto Hold

Needham analyst Mike Matson reiterates Hologic from Hold to Hold.

Vaata rohkem
Needham Reiterates Hold on Hologicto Hold
BusinessWire

Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients

Completed assessment of more than 2,800 patients highlights the profound impact of the test in helping to predict the likelihood of extended endocrine therapy benefit for patients with HR+ breast cancer to support more

Vaata rohkem
Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Tõusev

Uuendatud kell: 12. juuni 2025, 13:54

LangevNeutraalneTõusev

68.0% Kindlus

Risk ja kauplemine

Riskitase1/5
Madal risk
Sobib
Konservatiivne
Kauplemisjuhend

Sisenemispunkt

$64.34

Võta kasum

$68.60

Peata kahjum

$58.10

Põhitegurid

PDI 5.2 on MDI 4.7 kohal ADX-iga 19.2, mis viitab tõusutrendile
Praegune hind on tugitasemele ($64.34) äärmiselt lähedal, mis viitab tugevale ostuvõimalusele
Kauplemismaht on 4.4x keskmisest (38,759), mis viitab äärmiselt tugevale ostusurvele
MACD -0.0632 on signaalijoone -0.0979 kohal, mis viitab tõusvale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.